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Abstract
Backgrounds: Preoperative chemotherapy (PCT) and chemoradiotherapy (PCRT) showed promising results for
gastric cancers. However, the influence of preoperative adverse events (AEs) on postoperative complications
remains unknown. The aim of this study was to identify correlations between them.
Methods: Clinical data and laboratory findings were retrieved retrospectively for 115 patients who underwent
gastrectomy after PCT or PCRT between 2010 and 2013. Preoperative AEs and postoperative complications were
classified according to the Common Terminology Criteria for Adverse Events (CTCAE) and Clavien-Dindo (CD)
grading systems, respectively. Correlations between CTCAE grades and CD grades were analyzed, and clinical data
and laboratory findings were compared among three groups classified according to CD grades: CD0, CD1/2, and
CD3/4.
Results: There were 61 (53.0 %) patients in the CD0 group, 44 (38.3 %) patients in the CD1/2 group, and 10 (8.7 %)
patients in the CD3/4 group. The CTCAE grades did not correlate with the CD grades. Only estimated blood loss
(P = 0.019) and transfusion rate (P < 0.001) differed among the three CD groups.
Conclusion: There are no correlations between pre- and post-operative adverse events in the terms of severity
grades in patients with advanced or metastatic gastric cancer who underwent gastrectomy after PCT or PCRT.
Meticulous intraoperative manipulations should be emphasized.
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Background
Gastric cancer is the fifth most prevalent cancer world-
wide, and more than 70 % of them occur in less developed
countries [1], where they are often diagnosed at an ad-
vanced stage. D2 gastrectomy is regarded as the standard
surgical treatment for locally advanced gastric cancer
(AGC) based on randomized controlled trials [2, 3]. How-
ever, further treatment in addition to surgery is required
to improve patient survival. The kind of additional
treatment varies in different parts of the world: in
East Asia, adjuvant chemotherapy after D2 gastrec-
tomy is standard treatment for AGC [4, 5], whereas
perioperative chemotherapy or postoperative chemora-
diotherapy with gastrectomy is standard treatment in
the West [6–8].
Recently, the use of preoperative chemotherapy (PCT)
has gained increasing interest because of its possible ad-
vantages: 1) tumor down-staging increases the possibility
of achieving complete surgical resection, 2) early appli-
cation of chemotherapy may be effective in controlling
micrometastases, 3) patients are more tolerable to
chemotherapy before surgery, 4) the delivery of
* Correspondence: sunghoonn@yuhs.ac
Shuang-Xi Li and Sang Hyuk Seo are joint first authors.
†Equal contributors
1Department of Surgery, Yonsei University Health System, Yonsei University
College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 120-752 Seoul, South Korea
Full list of author information is available at the end of the article
© 2016 Li et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. BMC Cancer  (2016) 16:29 
DOI 10.1186/s12885-016-2066-y
chemotherapeutic drugs will be enhanced because the
blood supply to the tumor is intact, and 5) responses to
chemotherapy are easily detected. PCT may even be use-
ful for select patients with metastatic gastric cancer
(MGC) prior to surgery [9, 10].
Despite these potential advantages, adverse events
(AEs) due to PCT or preoperative chemoradiotherapy
(PCRT) leading to deterioration of a patient’s physical
condition could limit the ability to tolerate surgery. This
is particularly relevant, as previously reported incidences
of severe AEs ranged from 23.8 to 37.6 % [6, 7]. Thus,
there are concerns that PCT or PCRT could increase
postoperative morbidity [11]. Although postoperative
morbidity after PCT or PCRT has been previously
reported to be similar to that noted with surgery alone
[6, 7, 12], to our knowledge, no previous studies have
addressed the issue of whether preoperative AEs in-
crease the likelihood or severity of postoperative compli-
cations. The aim of this study was to analyze the
relationship between preoperative AEs and postoperative
complications in patients who underwent gastrectomy
for AGC or MGC after receiving PCT or PCRT.
Methods
Patients
Patients were eligible for inclusion in this study if they
had histologically-proven primary AGC or MGC, re-
ceived initial PCT or PCRT, and underwent gastrectomy
plus lymphadenectomy at Severance Hospital of Yonsei
University between January 2010 and December 2013.
The exclusion criteria included the presence of organ
dysfunction before initial PCT or PCRT and surgery per-
formed on an emergency basis. No comparative analysis
was made to gastric cancer patient undergoing gastrec-
tomy plus lymphadenectomy who did not receive initial
PCT or PCRT. The clinical-pathological characteristics
and laboratory investigations were retrieved from
electronic medical records. The times for which data
Fig. 1 Study flow diagram. PCT, preoperative chemotherapy; PCRT, preoperative chemoradiotherapy
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were collected are illustrated in Fig. 1. The study was
performed in accordance with the Declaration of
Helsinki, and was reviewed and approved by the Institu-
tional Review Board of Severance Hospital, Yonsei Uni-
versity College of Medicine (4-2011-0991).
The regimens for PCT or PCRT varied from single-
agent to triple-agent, they involved the use of fluoro-
uracil, platinum, taxanes, and/or irinotecan. Intensity
modulated radiation was performed using a dose of
40–45 Gy for PCRT. Since all patients received at
least one type of fluorouracil-based regimen, we classified
the chemotherapy regimens as platinum-containing,
taxane-containing, containing both platinum and taxane,
and others.
The operations included radical and palliative surger-
ies. As described in the Japanese Gastric Cancer Treat-
ment Guidelines Version 3.0 [13], radical gastrectomy
included resection of at least two-thirds of the stomach
and peri-gastric lymphadenectomy with D2 extension.
Palliative gastrectomy included resection of the entire
gastric lesion or total gastrectomy plus lymphadenec-
tomy with at least D1 extension.
Baseline and preoperative evaluations
The time point definitions for baseline and preoperative
evaluations were the most recent time before the initi-
ation of PCT or PCRT and the surgery (after the final
cycle) respectively. The laboratory investigations were
collected for evaluations and included 3 categories of
routine blood tests:
(1) Complete blood count: hemoglobin, white blood
cell, neutrophil, lymphocyte, and platelet.
(2) Hepatorenal function: albumin, alanine
transaminase, aspartate transaminase, alkaline
phosphatase, and serum creatinine.
(3) Coagulation function: activated partial
thromboplastin time, prothrombin, and
international normalized ratio.
Additionally, we determined the neutrophil lymphocyte
ratio (NLR), platelet lymphocyte ratio (PLR), and prognos-
tic nutritional index (PNI), to evaluate the systemic inflam-
matory and nutritional status. Preoperatively, C-reactive
protein was also recorded, and Glasgow Prognostic Score
Table 1 Clinical characteristics and preoperative treatmentsa
CD0 group (n = 61) CD1/2 group (n = 44) CD3/4 group (n = 10) Total (n = 115) P Value
Ageb (year) 56.0 (27.0–78.0) 56.0 (26.0–76.0) 58.5 (41.0–75.0) 56.0 (26.0–78.0) 0.467
Gender 0.452
Male 36 (59.0) 31 (70.5) 7 (70.0) 74 (64.3)
Female 25 (41.0) 13 (29.5) 3 (30.0) 41 (35.7)
BMI before surgeryb (kg/m2) 21.9 (17.3–30.7) 23.1 (17.1–32.4) 21.1 (16.9–29.0) 22.3 (16.9–32.4) 0.272
Tumor location 0.109
Proximal one-third 12 (19.7) 21 (47.7) 2 (20.0) 35 (30.4)
Middle one-third 18 (29.5) 8 (18.2) 3 (30.0) 29 (25.2)
Distal one-third 23 (37.7) 12 (27.3) 4 (40.0) 39 (33.9)
Whole 8 (13.1) 3 (6.8) 1 (10.0) 12 (10.4)
Preoperative treatment 0.881
PCT 50 (82.0) 34 (77.3) 8 (80.0) 92 (80.0)
PCRT 11 (18.0) 10 (22.7) 2 (20.0) 23 (20.0)
Cyclesb 5.0 (2.0–20.0) 7.0 (2.0–19.0) 7.5 (2.0–21.0) 5.0 (2.0–21.0) 0.082
Durationb (month) 3.1 (1.2–15.6) 4.5 (1.2–18.0) 5.4 (1.2–15.2) 3.6 (1.2–18.0) 0.061
Interval timeb (month) 1.1 (0.4–5.7) 1.0 (0.4–4.5) 1.2 (0.5–2.4) 1.1 (0.4–5.7) 0.167
Chemotherapy regimen 0.922
Platinum-containing 38 (62.3) 25 (56.8) 8 (80.0) 71 (61.7)
Taxane-containing 7 (11.5) 6 (13.6) 1 (10.0) 14 (12.2)
Containing both platinum and taxane 14 (23.0) 11 (25.0) 1 (10.0) 26 (22.6)
Others 2 (3.3) 2 (4.5) 0 (0.0) 4 (3.5)
Postoperative hospital stayb (day) 8.0 (5.0–12.0) 10.0 (7.0–27.0) 19.0 (11.0–29.0) 9.0 (5.0–29.0) <0.001
BMI body mass index, PCRT preoperative chemoradiotherapy, PCT, preoperative chemotherapy
aData are presented as number (percentage) unless indicated otherwise
bData are presented as median (range)
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(GPS) and Prognostic Index (PI) were rated. All these
values and factors were calculated and rated as described
previously [14].
Preoperative adverse events evaluation
Only the AEs based on objective laboratory investiga-
tions were classified according to the Common Termin-
ology Criteria for Adverse Events (CTCAE) Version 4.03
[15], and they were anemia, leukopenia, neutropenia, fe-
brile neutropenia, lymphocytopenia, thrombocytopenia,
increased transaminase, and increased serum creatinine.
The grade was determined by the highest CTCAE grade
for each event, and the “Total AEs” grade referred to the
highest CTCAE grade for all AEs in the study. Further-
more, AEs within 30 days before surgery were evaluated
in an attempt to identify correlations between abnormal
Table 2 Surgical and pathological characteristics a
CD0 group (n = 61) CD1/2 group (n = 44) CD3/4 group (n = 10) Total (n = 115) P Value
Surgical type 0.672
Open 55 (90.2) 42 (95.5) 9 (90.0) 106 (92.2)
MIS 6 (9.8) 2 (4.5) 1 (10.0) 9 (7.8)
Gastrectomy 0.219
Subtotal 31 (50.8) 15 (34.1) 5 (50.0) 51 (44.3)
Total 30 (49.2) 29 (65.9) 5 (50.0) 64 (55.7)
Surgical radicality 0.802
Radical 37 (60.7) 29 (65.9) 7 (70.0) 73 (63.5)
Palliative 24 (39.3) 15 (34.1) 3 (30.0) 42 (36.5)
Lymphadenectomy 0.504
D2 47 (77.0) 31 (70.5) 8 (80.0) 86 (74.8)
D1 plus 13 (21.3) 10 (22.7) 1 (10.0) 24 (20.9)
D1 1 (1.6) 3 (6.8) 1 (10.0) 5 (4.3)
Combined resection 0.592
Yes 12 (19.7) 7 (15.9) 3 (30.0) 22 (19.1)
No 49 (80.3) 37 (84.1) 7 (70.0) 93 (80.9)
EBLb (mL) 95 (28–300) 126 (30–609) 269 (50–640) 100 (28–640) 0.017
Transfusion <0.001
Yes 0 (0.0) 17 (38.6) 1 (10.0) 18 (15.7)
No 61 (100.0) 27 (61.4) 9 (90.0) 97 (84.3)
Borrmann type 0.524
I 6 (9.8) 2 (4.5) 2 (20.0) 10 (8.7)
II 12 (19.7) 10 (22.7) 1 (10.0) 23 (20.0)
III 32 (52.5) 20 (45.5) 6 (60.0) 58 (50.4)
IV 11 (18.0) 12 (27.3) 1 (10.0) 24 (20.9)
Lauren type 0.569
Intestinal 30 (49.2) 23 (52.3) 6 (60.0) 59 (51.3)
Diffuse 26 (42.6) 18 (40.9) 2 (20.0) 46 (40.0)
Mixed 5 (8.2) 3 (6.8) 2 (20.0) 10 (8.7)
TNM Stage 0.846
yp 0 4 (6.6) 1 (2.3) 1 (10.0) 6 (5.2)
yp Ia-Ib 14 (23.0) 7 (15.9) 1 (10.0) 22 (19.1)
yp IIa-IIb 6 (9.8) 6 (13.6) 2 (20.0) 14 (12.2)
yp IIIa-IIIc 15 (24.6) 15 (34.1) 3 (30.0) 33 (28.7)
yp IV 22 (36.1) 15 (34.1) 3 (30.0) 40 (34.8)
EBL, Estimated blood loss; MIS, Minimal invasive surgery
aData are presented as number (percentage) unless indicated otherwise
bData are presented as median (range)
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physical conditions in the month prior to surgery and
postoperative complications.
Postoperative complications evaluation
Postoperative complications within 30 days after surgery
were classified according to the Clavien-Dindo (CD)
grading system [16]. In our study, pulmonary-related
complications included atelectasis, pleural effusion, or
pneumonia, and infection-related complications consisted
of gastrointestinal (GI) tract leakage, abdominal ab-
scess, wound infection, pneumonia, or pyelonephritis.
Patients with a temperature >38.5° centigrade and in
whom other complications were subsequently ex-
cluded were diagnosed with an “unexplained fever”,
which was classified as a grade 1 complication. The
patients were assigned to one of the following three
groups based on the severity of postoperative compli-
cations: no complications (CD0 group); grade 1 or 2
Table 3 Incidence of AEs during PCT or PCRT according to CTCAE and Clavien-Dindo gradesa
CD0 group (n = 61) CD1/2 group (n = 44) CD3/4 group (n = 10) Total (n = 115) P Value
Anemia 0.099
Grade 0 6 (5.2) 6 (5.2) 0 (0.0) 12 (10.4)
Grade 1/2 48 (41.7) 27 (23.5) 6 (5.2) 81 (70.4)
Grade 3/4 7 (6.1) 11 (9.6) 4 (3.5) 22 (19.1)
Leukopenia 0.326
Grade 0 24 (20.9) 9 (7.8) 4 (3.5) 37 (32.2)
Grade 1/2 21 (18.3) 21 (18.3) 3 (2.6) 45 (39.1)
Grade 3/4 16 (13.9) 14 (12.2) 3 (2.6) 33 (28.7)
Neutropenia 0.244
Grade 0 16 (13.9) 4 (3.5) 3 (2.6) 23 (20.0)
Grade 1/2 19 (16.5) 16 (13.9) 3 (2.6) 38 (33.0)
Grade 3/4 26 (22.6) 24 (20.9) 4 (3.5) 54 (47.0)
Febrile neutropenia 0.829
Grade 0 49 (42.6) 35 (30.4) 9 (7.8) 93 (80.9)
Grade 3/4 12 (10.4) 9 (7.8) 1 (0.9) 22 (19.1)
Lymphocytopenia 0.748
Grade 0 10 (8.7) 9 (7.8) 2 (1.7) 21 (18.3)
Grade 1/2 41 (35.7) 29 (25.2) 5 (4.3) 75 (65.2)
Grade 3/4 10 (8.7) 6 (5.2) 3 (2.6) 19 (16.5)
Thrombocytopenia 0.798
Grade 0 39 (33.9) 26 (22.6) 8 (7.0) 73 (63.5)
Grade 1/2 19 (16.5) 16 (13.9) 2 (1.7) 37 (32.2)
Grade 3/4 3 (2.6) 2 (1.7) 0 (0.0) 5 (4.3)
Increased ALT/AST 0.718
Grade 0 34 (29.6) 28 (24.3) 6 (5.2) 68 (59.1)
Grade 1/2 27 (23.5) 16 (13.9) 4 (3.5) 47 (40.9)
Increased Scr 1.000
Grade 0 58 (50.4) 41 (35.7) 9 (7.8) 108 (93.9)
Grade 1/2 3 (2.6) 3 (2.6) 1 (0.9) 7 (6.1)
Total AEs 0.138
Grade 0 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.9)
Grade 1/2 29 (25.2) 11 (9.6) 3 (2.6) 43 (37.4)
Grade 3/4 32 (27.8) 32 (27.8) 7 (6.1) 71 (61.7)
AEs adverse events, ALT alanine transaminase, AST aspartate transaminase, CTCAE common terminology criteria for adverse events, PCRT preoperative
chemoradiotherapy, PCT preoperative chemotherapy, Scr serum creatinine
aData are presented as number (incidence)
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complications (CD1/2 group); and grade 3 or 4 com-
plications (CD3/4 group).
Statistical analyses
Nominal data are presented as number (percentage),
scale data are presented as median (range), and AEs and
complications are presented as number (incidence).
Differences in nominal data and AEs among groups
were detected by Chi-square tests or Fisher’s exact tests
and differences in scale data among groups were de-
tected by Kruskal-Wallis tests. Correlation analyses be-
tween CD grades and ordinal data, including CTCAE
grades, GPS, and PI, were performed by Spearman’s
correlation tests. A P value less than 0.05 (two-sided)
was considered statistically significant. All analyses
were performed with SPSS® version 22.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Clinical-pathological characteristics
A total of 115 patients were included in this study.
There were 74 males (64.3 %) and 41 females (35.7 %).
The majority of patients received PCT, whereas only 23
patients (20.0 %) received PCRT. The postoperative stay
differed among the three groups (P < 0.001). PCT or
PCRT consisted of a median of 5.0 (1.0–21.0) cycles, and
there were no significant differences among groups re-
garding other treatment-related parameters (Table 1).
The operations primarily involved open surgery, total
gastrectomy, radical resection, and D2 lymphadenec-
tomy. Only estimated blood loss (EBL) (P = 0.017) and
intra/postoperative transfusion rate (P < 0.001) were sig-
nificantly different among groups (Table 2).
Incidence and type of preoperative adverse events
Overall, the incidence rates for AEs during PCT or
PCRT were as follows (in descending order): anemia
(89.6 %, 103/115), lymphocytopenia (81.7 %, 94/115), neu-
tropenia (80 %, 92/115), leukopenia (67.8 %, 78/115), in-
creased transaminase (40.9 %, 47/115), thrombocytopenia
(32.2 %, 37/115), febrile neutropenia (19.1 %, 22/115), and
increased serum creatinine (6.1 %, 7/115). The total AEs
incidence was 99.1 % (114/115). For serious AEs classified
as CTCAE grade 3/4, the incidence rates were as follows
Table 4 Incidence of AEs within 30 days before surgery according to CTCAE and Clavien-Dindo gradesa
CD0 group (n = 61) CD1/2 group (n = 44) CD3/4 group (n = 10) Total (n = 115) P Value
Anemia 0.724
Grade 0 23 (20.0) 13 (11.3) 2 (1.7) 38 (33.0)
Grade 1/2 36 (31.3) 30 (26.1) 8 (7.0) 74 (64.3)
Grade 3/4 2 (1.7) 1 (0.9) 0 (0.0) 3 (2.6)
Leukopenia 0.196
Grade 0 38 (33.0) 27 (23.5) 10 (8.7) 75 (65.2)
Grade 1/2 19 (16.5) 15 (13.0) 0 (0.0) 34 (29.6)
Grade 3/4 4 (3.5) 2 (1.7) 0 (0.0) 6 (5.2)
Neutropenia 0.740
Grade 0 38 (33.0) 26 (22.6) 8 (7.0) 72 (62.6)
Grade 1/2 16 (13.9) 12 (10.4) 2 (1.7) 30 (26.1)
Grade 3/4 7 (6.1) 6 (5.2) 0 (0.0) 13 (11.3)
Lymphocytopenia 0.720
Grade 0 31 (27.0) 19 (16.5) 6 (5.2) 56 (48.7)
Grade 1/2 27 (23.5) 24 (20.9) 4 (3.5) 55 (47.8)
Grade 3/4 3 (2.6) 1 (0.9) 0 (0.0) 4 (3.5)
Thrombocytopenia 0.577
Grade 0 45 (39.1) 34 (29.6) 9 (7.8) 88 (76.5)
Grade 1/2 16 (13.9) 10 (8.7) 1 (0.9) 27 (23.5)
Total AEs 0.421
Grade 0 14 (12.2) 8 (7.0) 1 (0.9) 23 (20.0)
Grade 1/2 36 (31.3) 28 (24.3) 9 (7.8) 73 (63.5)
Grade 3/4 11 (9.6) 8 (7.0) 0 (0.0) 19 (16.5)
AEs adverse events, CTCAE common terminology criteria for adverse events
aData are presented as number (incidence)
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(in descending order): neutropenia (47.0 %, 54/115),
leukopenia (28.7 %, 33/115), anemia (19.1 %, 22/115),
lymphocytopenia (16.5, 19/115), febrile neutropenia
(12.2 %, 14/115), and thrombocytopenia (4.3 %, 5/115).
The total serious AEs incidence was 61.7 % (71/115).
The distributions of AE severity (ratios of grade 0,
grade 1/2, and grade 3/4) were comparable among
groups (Table 3).
For AEs within 30 days before surgery, the AE incidence
rates were as follows (in descending order): anemia
(67.0 %, 77/115), lymphocytopenia (51.3 %, 59/115), neu-
tropenia (37.4 %, 43/115), leukopenia (34.8 %, 40/115),
and thrombocytopenia (23.5 %, 27/115). The total AEs in-
cidence was 80.0 % (92/115), including a 16.5 % (19/115)
incidence of grade 3/4 AEs. The distributions of AE sever-
ity (ratios of grade 0, grade 1/2, and grade 3/4) did not dif-
fer among groups (Table 4).
Incidence and type of postoperative complications
There was no postoperative mortality, and the morbidity
rate was 47.0 % (54/115). The most frequent complication
was pulmonary-related complications, the most common
minor complications (CD1/2) were pulmonary-related
complications and transfusion, and the most common ser-
ious complication (CD3/4) was GI tract leakage/abscess
(Table 5).
Correlation analyses of preoperative adverse events and
postoperative complications
Correlation analyses were performed between the
CTCAE grade of AEs during PCT or PRCT and the CD
grade of postoperative complications using Spearman’s
correlation tests. The results revealed no correlations be-
tween the two grading systems (Fig. 2). Similarly, no cor-
relations were noted when comparing the CTCAE
grades of AEs within 30 days before operation and the
CD grade of postoperative complications (Fig. 3).
Differences in laboratory tests, inflammation-based
prognostic scores, and nutrition index
During baseline and preoperative evaluations, all labora-
tory test results were comparable among groups, with
no statistically significant differences. Similarly, the NLR,
PLR, and PNI at baseline and preoperatively failed to ex-
hibit significant differences among groups. According to
Spearman’s correlation tests, neither the preoperative
GPS nor PI was correlated with the postoperative com-
plications CD grade (Table 6).
Discussion
In this retrospective study, we focused on the relation-
ship between preoperative AEs and postoperative com-
plications in patients with AGC or MGC who received
PCT or PCRT. The incidence of both total AEs and total
serious AEs were extremely high compared to previous
studies [6, 7, 17]. The 5.0 median cycles of PCT or
PCRT in our study may have contributed to this discrep-
ancy, as it is reasonable to expect a higher incidence of
AEs in our population who received extensive preopera-
tive treatment. Even in the time period very close to sur-
gery (within 30 days before surgery), we observed a
relatively high incidence of total AEs. The AEs associ-
ated with PCT or PCRT would definitely negatively
affect a patient’s physical condition, which may subse-
quently influence the postoperative course; thus, con-
cerns have arisen about the safety of performing
gastrectomy and lymphadenectomy for such vulnerable
patients.
A correlation between poor physical status and post-
operative morbidity was previously reported by Jung
et al. [18], who indicated that patients with preoperative
anemia had a higher morbidity rate after radical gastrec-
tomy than patients without. By contrast, the CTCAE
grades for AEs in our study did not correlate with post-
operative CD grades. A similar result was reported by
Reim et al. [19], who noted that preoperative leukopenia
due to neoadjuvant chemotherapy had no significant effect
Table 5 Postoperative complicationsa
CD1/2 group
(n = 44)
CD3/4 group
(n = 10)
Totalb
(n = 115)
Non-surgery-related
Pulmonary-related 17 (14.8) 3 (2.6) 20 (17.4)
Deep vein thrombus 1 (0.9) 0 (0.0) 1 (0.9)
Unexplained fever 7 (6.1) 0 (0.0) 7 (6.1)
Transfusion 17 (14.8) 1 (0.9) 18 (15.7)
Othersc 3 (2.6) 1 (0.9) 4 (3.5)
Surgery-related
Wound discharge/infection 5 (4.3) 2 (1.7) 7 (6.1)
Intestinal obstruction 3 (2.6) 1 (0.9) 4 (3.5)
Fluid collection 9 (7.8) 1 (0.9) 10 (8.7)
Gastrointestinal tract leakage/
abscess
1 (0.9) 6 (5.2) 7 (6.1)
Complication type
Not infection-related 26 (22.6) 3 (2.6) 29 (25.2)
Infection-related 12 (10.4) 7 (6.1) 19 (16.5)
Clavien-Dindo grade
Grade 1 15 (13.0) NA 15 (13.0)
Grade 2 29 (25.2) NA 29 (25.2)
Grade 3 NA 8 (7.0) 8 (7.0)
Grade 4 NA 2 (1.7) 2 (1.7)
NA not applicable
aData are presented as number (incidence)
bIncluded 61 patients in CD0 group
cIncluded pyelonephritis, hydronephrosis, re-admission for nutrition support,
and renal dysfunction
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on postoperative complications after total gastrectomy
plus D2 lymphadenectomy. However, because there were
many discrepancies in patient selection, evaluation cri-
teria, surgical procedures, and diagnostic standards among
the previous studies, it was difficult to make definitive
conclusions from these studies. The results of our current
study can reduce concerns regarding the safety of surgery
after PCT or PCRT, but they cannot eliminate them. A
well-designed clinical trial is required to provide firm con-
clusions regarding this issue.
In previous studies, postoperative morbidity rates
after gastrectomy plus lymphadenectomy varied from
25.7 to 45.7 % in patients who underwent PCT or PCRT
[6, 7, 11, 12]. The morbidity rate of 47.0 % in our study
is relatively high but still comparable to the rate noted
in a previous report from our institute [11]. In the
present study, a high percentage of patients had stage
IV cancer and underwent total gastrectomy and com-
bined resection, which suggests that their surgery was
more complicated. Postoperative morbidity may have
been increased for this reason. It should be noted that
the most common minor (CD1/2) complication in our
study was pulmonary-related complications, a type of
non-surgery-related complications. It is quite possible
that these complications were related to a poor physical
status of patients after PCT or PCRT. Additionally, the
relatively low incidence of serious (CD3/4) complica-
tions (8.7 %) highlights the advantage of performing
such complex surgery in a high-volume center.
Higher intraoperative blood loss and operative transfusion
rates were previously reported to correlate with postopera-
tive morbidity after gastrectomy and lymphadenectomy [11,
20]. In terms of CD grades, we found significant differences
among groups for EBL and transfusion rates. Patients with
greater CD grades had a greater EBL. In the CD grading
system, transfusion is classified as a grade 2 morbidity,
which was why the transfusion rate was highest in our
CD1/2 group. Generally, a higher blood loss reflects in-
creased surgical difficulty and correlates with a higher trans-
fusion rate. For the same level of surgical complexity,
Fig. 2 Stacked percentage bar charts for AEs during PCT and PCRT. AEs, adverse events; ALT, alanine transaminase; AST, aspartate transaminase;
CTCAE, Common Terminology Criteria for Adverse Events; PCRT, preoperative chemoradiotherapy; PCT, preoperative chemotherapy; Scr serum
creatinine. Correlation analysis was performed by Spearman’s correlation test. The charts from a-i refer to the stacked percentage for anemia,
leukopenia, neutropenia, febrile neutropenia, lymphocytopenia, thrombocytopenia, increased AST/ALT, increased Scr, and total AEs respectively
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gastrectomy could be more difficult in patients who re-
ceived PCT or PCRT because of peri-tumoral fibrosis,
edema, or a bulky tumor mass. These factors are known to
increase the need for surgical technique and experience. In-
dependent of other factors related to postoperative morbid-
ity, the surgical technique and quality are definitely crucial
determinants of outcome. Meticulous manipulations during
surgery should reduce trauma, operative blood loss, and ul-
timately morbidity.
In recent years, certain factors derived from routine la-
boratory investigations have been reported to manifest
prognostic values in predicting the outcomes for patients
with AGC and MGC. These factors include white blood
cell and neutrophil counts, NLR, PLR, GPS, and PNI [14,
21, 22]. Importantly, Jiang et al. [23] reported that the se-
verity of postoperative complication could influence the
survival time for patients with gastric cancer, thereby sug-
gesting the possibility of a direct link between the severity
of postoperative morbidity and long-term prognostic fac-
tors. However, in our study, all laboratory findings,
inflammation-based prognostic scores, and PNI did not dif-
fer among groups. The discrepancy is quite possibly be-
cause of the PCT or PCRT, as the baseline parameters no
longer represented the patient’s actual preoperative status,
and the preoperative parameters could have been altered to
varying degrees. Therefore, the above factors do not appear
to be useful for predicting the postoperative morbidity for
patients who received PCT or PCRT.
Limitations of this study include the relatively small num-
ber of patients and the natural drawbacks associated with
all retrospective studies. There was substantial heterogen-
eity among patients and interventions. Firstly, patients with
serious preoperative AEs tended to be under intensive clin-
ical observations and may have received therapeutic inter-
ventions, which may have influenced postoperative
morbidity. Secondly, the extent of surgery differed among
patients. The surgical extent itself can influence postopera-
tive morbidity, and should be well defined in a future study.
Thirdly, the PCT and PCRT had different systemic and
local effects, and each specific regimen also had unique tox-
icities. The variable treatments and regimens may have led
to differing physiological alterations, even under the same
AE grade. Fourthly, there were a number of patients who
received preoperative treatment with PCT or PCRT but
failed to subsequently proceed on to surgery. Data regard-
ing the exact number of these patients nor the reasons why
they did not subsequently proceed on to surgery was not
included within the current study analysis. Therefore, had
these individuals proceeded on to surgery after receiving
preoperative treatment with PCT or PCRT, the observed
degree and severity of postoperative complications that oc-
curred in the overall study group could have been substan-
tially different. However, there is no realistic way for us to
make any such inferences into how preoperative AEs in
this particular group of patients may have impacted upon
the overall postoperative complications observed in the
entire study group if this group of patients had theoretic-
ally proceeded on to surgery. Lastly, despite the limitations
of our study, it is our belief that our use of both the
CTCAE system for classifying AEs and the CD grading
Fig. 3 Stacked percentage bar charts for AEs within 30 Days before surgery. AEs, adverse events; CTCAE, Common Terminology Criteria for Adverse
Events; PCRT, preoperative chemoradiotherapy; PCT, preoperative chemotherapy. Correlation analysis was performed by Spearman’s correlation test. The
charts from a-f refer to the stacked percentage for anemia, leukopenia, neutropenia, lymphocytopenia, thrombocytopenia, and total AEs respectively
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Table 6 Differences in laboratory tests, inflammation-based prognostic scores, and nutrition index according to Clavien-Dindo gradesa
CD0 group (n = 61) CD1/2 group (n = 44) CD3/4 group (n = 10) P Value
Baseline
HB (g/L) 129 (66–155) 121 (64–170) 112 (72–159) 0.284
WBC (×109/L) 5.9 (3.6–13.9) 6.4 (3.6–14.2) 8.1 (3.9–10.2) 0.109
NEU (×109/L) 3.6 (2.2–10.9) 3.9 (2.0–11.7) 4.8 (1.4–7.7) 0.136
LYM (×109/L) 1.7 (0.7–3.1) 1.8 (0.6–3.0) 2.0 (1.4–2.4) 0.238
PLT (×109/L) 298.0 (96.0–639.0) 295.0 (141.0–599.0) 301.5 (166.0–438.0) 0.784
ALB (g/L) 42.0 (35.0–49.0) 41.0 (28.0–47.0) 39.0 (25.0–48.0) 0.631
ALT (U/L) 14.0 (5.0–75.0) 14.5 (5.0–58.0) 13.0 (7.0–59.0) 0.888
AST (U/L) 17.0 (10.0–56.0) 15.0 (8.0–73.0) 19.5 (10.0–37.0) 0.473
ALP (U/L) 56.0 (24.0–109.0) 59.5 (25.0–123.0) 71.5 (31.0–99.0) 0.137
Scr (mg/dL) 0.82 (0.48–1.20) 0.86 (0.53–1.28) 0.81 (0.68–1.59) 0.593
aPTT (second) 29.8 (23.0–37.2) 29.6 (24.9–38.6) 28.6 (24.9–33.1) 0.315
PT (second) 10.9 (9.3–12.8) 11.0 (9.0–13.1) 11.1 (9.5–12.7) 0.765
INR 0.96 (0.82–1.12) 0.97 (0.79–1.16) 0.98 (0.84–1.11) 0.883
PNI 50.2 (40.4–61.8) 50.6 (34.2–60.0) 49.7 (33.0–60.2) 0.954
NLR 2.5 (0.7–6.6) 2.2 (1.0–9.5) 2.4 (0.7–7.8) 0.805
PLR 181.9 (67.6–557.7) 179.1 (73.8–487.0) 171.1 (78.3–256.9) 0.683
Preoperative
HB (g/L) 116 (86–152) 115 (76–160) 117 (91–125) 0.810
WBC (×109/L) 4.7 (2.3–11.7) 4.7 (2.7–11.9) 5.8 (3.0–9.7) 0.598
NEU (×109/L) 2.7 (0.7–8.8) 2.6 (1.2–9.1) 3.0 (1.5–7.8) 0.755
LYM (×109/L) 1.5 (0.5–3.4) 1.6 (0.4–2.7) 1.3 (0.6–2.9) 0.835
PLT (×109/L) 218.0 (73.0–398.0) 202.0 (91.0–583.0) 216.5 (167.0–276.0) 0.861
ALB (g/L) 40.0 (27.0–48.0) 39.5 (26.0–52.0) 39.0 (32.0–41.0) 0.541
ALT (U/L) 17.0 (6.0–72.0) 14.0 (6.0–52.0) 15.5 (11.0–43.0) 0.431
AST (U/L) 20.0 (12.0–75.0) 19.0 (11.0–42.0) 19.0 (12.0–42.0) 0.671
ALP (U/L) 61.5 (21.0–142.0) 59.5 (25.0–106.0) 63.5 (35.0–163.0) 0.887
Scr (mg/dL) 0.78 (0.43–1.39) 0.78 (0.38–1.55) 0.75 (0.63–1.34) 0.874
aPTT (second) 29.9 (24.2–41.5) 29.7 (20.7–37.5) 31.0 (26.1–34.6) 0.979
PT (second) 10.5 (9.4–13.1) 10.9 (9.4–13.4) 10.5 (9.6–11.7) 0.196
INR 0.93 (0.83–1.15) 0.97 (0.83–1.18) 0.94 (0.85–1.01) 0.147
CRPb (mg/L) 1.1 (0.3–51.1) 1.3 (0.4–68.6) 1.8 (0.5–13.9) 0.502
PNI 46.8 (30.5–59.9) 46.0 (33.2–62.1) 45.4 (37.2–54.3) 0.801
NLR 1.7 (0.6–9.6) 1.9 (0.6–9.7) 2.0 (0.8–10.1) 0.811
PLR 134.6 (38.2–574.1) 123.4 (44.7–640.7) 148.3 (66.1–392.1) 0.714
GPSb,c 0.804
Score 0 43 (81.1) 30 (76.9) 7 (87.5)
Score 1 8 (15.1) 6 (15.4) 0 (0.0)
Score 2 2 (3.8) 3 (7.7) 1 (12.5)
PIb,c 0.572
Score 0 49 (92.5) 35 (89.7) 7 (87.5)
Score 1 4 (7.5) 4 (10.3) 1 (12.5)
ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; CRP, C-reactive protein;
GPS, Glasgow Prognostic Score; HB, hemoglobin; INR, international normalized ratio; LYM, lymphocyte count; NEU, neutrophil count; NLR, neutrophil–lymphocyte ratio;
PI, Prognostic Index; PLR, platelet–lymphocyte ratio; PLT, platelet count; PNI, prognostic nutritional index; PT, prothrombin; Scr, serum creatinine; WBC, white blood
cell count
aData are presented as median (range) unless indicated otherwise
bData retrieved from 100 patients, including 53 patients in CD0 group, 39 patients in CD1/2 group, and 8 patients in CD3/4 group
cData are presented as number (percentage)
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system for classifying postoperative complications allowed
for minimizing any subjectivity to the analysis process of
the data included within the current study.
Conclusions
In summary, for patients with AGC and MGC who under-
went gastrectomy and lymphadenectomy, this study pro-
vided supportive evidence favoring the use of PCT or PCRT.
The CTCAE grades of preoperative AEs did not correlate
with the CD grades of postoperative complications. The
higher EBL and transfusion rate noted in patients with com-
plications emphasize the importance of meticulous manipu-
lations during surgery to reduce postoperative morbidity.
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